PTEN status in advanced colorectal cancer treated with cetuximab

BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Negri, F V, Bozzetti, C, Lagrasta, C A, Crafa, P, Bonasoni, M P, Camisa, R, Pedrazzi, G, Ardizzoni, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813733/
https://www.ncbi.nlm.nih.gov/pubmed/19953097
http://dx.doi.org/10.1038/sj.bjc.6605471
_version_ 1782176949234302976
author Negri, F V
Bozzetti, C
Lagrasta, C A
Crafa, P
Bonasoni, M P
Camisa, R
Pedrazzi, G
Ardizzoni, A
author_facet Negri, F V
Bozzetti, C
Lagrasta, C A
Crafa, P
Bonasoni, M P
Camisa, R
Pedrazzi, G
Ardizzoni, A
author_sort Negri, F V
collection PubMed
description BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab. RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001). CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.
format Text
id pubmed-2813733
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28137332011-01-05 PTEN status in advanced colorectal cancer treated with cetuximab Negri, F V Bozzetti, C Lagrasta, C A Crafa, P Bonasoni, M P Camisa, R Pedrazzi, G Ardizzoni, A Br J Cancer Short Communication BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab. RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001). CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised. Nature Publishing Group 2010-01-05 2009-12-01 /pmc/articles/PMC2813733/ /pubmed/19953097 http://dx.doi.org/10.1038/sj.bjc.6605471 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Negri, F V
Bozzetti, C
Lagrasta, C A
Crafa, P
Bonasoni, M P
Camisa, R
Pedrazzi, G
Ardizzoni, A
PTEN status in advanced colorectal cancer treated with cetuximab
title PTEN status in advanced colorectal cancer treated with cetuximab
title_full PTEN status in advanced colorectal cancer treated with cetuximab
title_fullStr PTEN status in advanced colorectal cancer treated with cetuximab
title_full_unstemmed PTEN status in advanced colorectal cancer treated with cetuximab
title_short PTEN status in advanced colorectal cancer treated with cetuximab
title_sort pten status in advanced colorectal cancer treated with cetuximab
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813733/
https://www.ncbi.nlm.nih.gov/pubmed/19953097
http://dx.doi.org/10.1038/sj.bjc.6605471
work_keys_str_mv AT negrifv ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT bozzettic ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT lagrastaca ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT crafap ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT bonasonimp ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT camisar ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT pedrazzig ptenstatusinadvancedcolorectalcancertreatedwithcetuximab
AT ardizzonia ptenstatusinadvancedcolorectalcancertreatedwithcetuximab

Ejemplares similares